CMS has extended the 2023 MIPS submission deadline to April 15, 2024.

Purchase your MIPSpro license by April 1 for access to Customer Support during submission season.

Act fast – time is running out!

34
Days
:
 
03
Hours
:
 
59
Minutes
:
 
46
Seconds

You missed out!

Healthmonix 2021 QCDR Quality Measures

Quality IdMeasure NameHigh PriorityMeasure TypeMeasure Descriptionhf:tax:specialty_measure_setshf:tax:collection_types
MBHR032021 MBHR Measure: Pain Interference Response utilizing PROMISYESPatient Reported Outcome (PRO)The percentage of adult patients (18 years of age or older) who report pain issues and demonstrated a response to treatment at one month from the index scoreDetails
HM102021 HM10: Outcomes of Hearing Loss TreatmentYESPatient Reported Outcome (PRO)Percentage of patients aged 50 years and older, who are screened with a hearing loss self-assessment tool that indicated an impact on hearing-related QoL AND if diagnosed with a mild or greater hearing loss in at least one ear or identified with a hearing loss, receive an audiologic care plan and hearing loss intervention(s) AND report a meaningful clinically important difference (MCID) improvement in hearing-related quality of life (QoL) within 12 months of hearing loss diagnosis.Details
HM112021 HM11: Outcomes of Treatment of Subjective TinnitusYESPatient Reported Outcome (PRO)Percentage of patients aged 18 years and older who are screened for bothersome subjective tinnitus AND, if patient reports symptoms, assessed with clinical evaluation for tinnitus severity and impact on hearing-related quality of life (HRQoL) using a validated self-assessment tool AND, if identified with tinnitus that impacts the patients HRQoL, receive a tinnitus-related care plan, and tinnitus-related intervention(s), treatment(s), or management AND who report a meaningful clinically important difference (MCID) improvement in the impact of tinnitus on the patient’s HRQoL within 12 months of initial identification.Details
HM122021 HM12: Outcomes of Treatment of Benign Paroxysmal Positional VertigoYESPatient Reported Outcome (PRO)Percentage of patients aged 18 years and older, who report benign paroxysmal positional vertigo (BPPV)-related symptoms and are screened with a dizziness assessment questionnaire and undergo positional nystagmus testing AND, if diagnosed or identified with BPPV, received a BPPV-related care plan and vestibular intervention(s) or treatment(s) AND who have an improvement in nystagmus or report an improvement in BPPV-related symptoms, and report a meaningful clinically important difference (MCID) improvement of BPPV-related quality of life (QoL).Details
HM042021 HM4: Functional Status Change for Patients With Upper-limb Functional Status DeficitYESOutcomePercentage of patients aged 13 years or older with a functional deficit related to the upper-limb who achieve a Minimal Clinically Important Difference (MCID) in QuickDASH or equivalent score that indicates a functional improvement greater than zero.Details
HM052021 HM5: Functional Status Change for Patients With Neck Functional Status DeficitYESOutcomePercentage of patients aged 18 years or older with a functional deficit related to the neck who achieve a Minimal Clinically Important Difference (MCID) in the Neck Disability Index (NDI) or equivalent score that indicates a functional improvement greater than zero.Details
HM062021 HM6: Functional Status Change for Patients With Low Back Functional Status DeficitYESOutcomePercentage of patients aged 18 years or older with a functional deficit related to the low back who achieve a Minimal Clinically Important Difference (MCID) in the Modified Oswestry Low Back Pain Questionnaire (ODI) or equivalent score that indicates a functional improvement greater than zero.Details
HM072021 HM7: Functional Status Change for Patients with Vestibular DysfunctionYESOutcomePercentage of patients aged 14 years and older diagnosed with vestibular dysfunction who achieve a Minimal Clinically Important Difference (MCID) as measured via the validated Dizziness Handicap Inventory or equivalent instrument to indicate functional, emotional, and physical improvementDetails
HM082021 HM8: Functional Status Change for Patients With Lower Extremity Functional Status DeficitYESPatient Reported Outcome (PRO)Percentage of patients aged 18 years or older with a functional deficit related to the lower extremity who achieve a Minimal Clinically Important Difference (MCID) in Lower Extremity Functional Scale (LEFS) score that indicates a functional improvement greater than zero.Details
HM092021 HM9: Functional Benefit of a Cochlear ImplantYESPatient Reported Outcome (PRO)Percentage of patients aged 18 years and older, who are evaluated for hearing loss and complete a hearing loss self-assessment tool that indicated an impact of hearing-related quality of life (QoL), and if diagnosed with a bilateral moderate to profound sensorineural hearing loss (SNHL) and less than 60% open set speech recognition are scheduled or referred for cochlear implant candidacy testing AND for patients who undergo cochlear implantation, demonstrate a meaningful clinically important difference (MCID) improvement in self-assessment of Hearing-related QoL or an improvement in speech recognition within 18 months of cochlear implant activation.Details